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Abstract
 
Fas is an apoptosis-signaling receptor molecule expressed in
vivo on thymocytes, liver, heart, and ovary. In vivo adminis-
tration of the anti-Fas Jo2 antibody in mice induces severe
apoptotic liver damage leading to fulminant hepatitis and
death. Linomide, a quinoline 3-carboxamide, inhibits apop-
tosis of B and T cells induced by various stimuli including
viruses, superantigens, and glucocorticoids. Mice treated
with linomide survived the lethal effect of anti-Fas anti-
body, did not accumulate ceramide in hepatocytes, and re-
covered liver structure and function within 96 h of anti-Fas
injection, as confirmed by histology and glutamic oxalacetic
transaminase, glutamic pyruvic transaminase, and lactate
dehydrogenase levels. Surviving mice showed severe deple-
tion of cortical thymocytes, but medullar thymic cells ex-
pressing high CD3 and Fas levels also survived the treat-
ment with anti-Fas in the presence of linomide. Heart, lung,
and ovary showed no signs of apoptosis promoted by Fas li-
gation. These results suggest that linomide prevents cell
death triggered by Fas ligation and can be useful for thera-
peutic intervention in fulminant hepatitis. (
 
J. Clin. Invest.
 
1996. 98:1245–1252.) Key words: apoptosis 
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Introduction
 
Apoptosis is believed to be the essential physiological process
underlying control of programmed cell death during embry-
onic development, cell differentiation, or tissue turnover.
Apoptosis is morphologically characterized by fragmentation
of the cell together with the nucleus, resulting in the formation
of apoptotic bodies which are subjected to phagocytosis (1, 2).
The Fas molecule is one of the identified cell surface molecules
which mediates external ligand-stimulated apoptosis (3, 4).
There is presently little information on the signaling mecha-
nisms that initiate the apoptotic response. Recently, however,
the sphingomyelin pathway leading to ceramide production
has been shown to participate in the early events in the apop-
totic cascade of TNF-
 
a
 
, ionizing radiation, and Fas-induced
programmed cell death (5).
Linomide is an immunomodulator which has been found to
inhibit apoptosis in vivo of peripheral T cells induced by vari-
ous stimuli: 
 
Staphylococcus aureus
 
 enterotoxin B, glucocorti-
coids (GC),
 
1
 
 and vaccinia virus (6, 7). The activity implicated
in prevention of apoptosis appears to be due to a metabolite,
since linomide is devoid of any antiapoptotic activity in vitro
(6). Linomide also reduces murine sensitivity for development
of septic shock (8). These life-preserving effects of linomide
may be related to partial inhibition of TNF production (6, 8),
which is effective at the transcriptional level as demonstrated
by semiquantitative PCR analysis. In contrast to cyclosporin A
and GC, linomide exerts immunostimulatory effects in several
systems and, in fact, antagonizes the immunosuppressive ef-
fects of cyclosporin A and GC in vivo (9, 10).
The Fas/Apo antigen (CD95) is a 45-kD single transmem-
brane receptor belonging to the family of the apoptosis-signal-
ing molecules which is expressed on a variety of neoplasic and
normal cells (3, 4, 11, 12), including those of thymus, heart,
liver, and ovary. In lymphoid cells, Fas is preferentially ex-
pressed on the cell surface after cellular activation and plays a
crucial role in the homeostasis of peripheral lymphocyte ex-
pansion, as well as in the apoptosis of autoreactive clones (13–
21). Cross-linking of Fas has been shown to activate an acidic
sphingomyelinase and to promote an increase in ceramide
concentration, suggested to be a mediator of apoptosis (5).
Furthermore, T cell receptor cross-linking by antibodies or su-
perantigens activates the Fas-Fas ligand (18–21) and promotes
cell death which is inhibited by linomide (6). Therefore, we
sought to identify the mechanism through which linomide pre-
vents apoptosis in a model system based on the in vivo admin-
istration of an anti-Fas antibody which provokes animal death
mediated by massive liver and thymocyte cell death. We show
that linomide rescues mice from death, prevents cell death in
liver as well as in medullar thymocytes, and prevents ceramide
accumulation in hepatocytes. We also show that, in contrast to
the case for the liver, Fas ligation does not trigger ceramide ac-
cumulation in thymocytes.
 
Methods
 
Mice and antibodies.
 
BALB/c mice derived from Jackson mice were
maintained and bred at the Centro Nacional de Biotecnologia
(Madrid, Spain) animal facilities under pathogen-free conditions us-
ing cages and sterile workbenches. All experiments were carried out
with 8–12-wk-old age- and sex-matched mice. Mice received injec-
tions of the Jo2 antibody (22).
 
Phenotypic characterization.
 
Thymuses were prepared by teasing
the tissue through a nylon screen. Red cells were lysed by osmotic shock
and single-cell suspensions prepared and stained with mAb against
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CD3
 
e 
 
(145C11, Pharmingen, San Diego, CA), anti-CD4, anti-CD8, or
Fas (Pharmingen), which were FITC- or PE-labeled as described (23).
 
Histological examination.
 
Histological analyses of liver and thy-
mus sections were prepared at different times after antibody injection
and were hematoxylin and eosin stained.
 
Determination of ceramide levels.
 
Appropriate liver and thymus
fragments were suspended and homogenized in PBS at 4
 
8
 
C. Lipids
were extracted with chloroform/methanol/hydrochloric acid (1 N)
(500:500:5, vol/vol) and centrifuged for 5 min at 500 
 
g
 
. Lipids in the
organic phase extract were then dried under N
 
2
 
 and thereafter soni-
cated in 10 mM Tris, pH 7.4. Ceramide was quantified by the diacyl-
glycerol (DAG) kinase as 
 
32
 
P incorporated upon ceramide phosphor-
ylation to ceramide-1-phosphate by DAG kinase (5). Purified
 
Escherichia coli
 
 DAG kinase (Calbiochem-Novabiochem Corp., La
Jolla, CA) in enzyme buffer (20 mM Tris-HCl, 10 mM dithiothreitol,
1.5 M NaCl, 250 mM sucrose, and 15% glycerol, pH 7.4) was added to
the organic phase extract. [
 
g
 
-
 
32
 
P]ATP (10 mM; 1,000 dpm/pmol) in
enzyme buffer was added to start the reaction. After 30 min at 22
 
8
 
C,
the reaction was terminated by extraction of lipids, as described
above. The lower organic phase was dried under N
 
2
 
. Ceramide-1-
phosphate was resolved by TCL using CHCl
 
3
 
/CH
 
3
 
OH/HAc (65:15:5,
vol/vol) as solvent and detected by autoradiography. Lipids were sep-
arated by TCL and radioactive spots were visualized by autoradiogra-
phy. Ceramide and DAG controls were included in the assay and
quantitative results for ceramide-1-phosphate accumulation were ob-
tained by autoradiograph scanning by comparison with a standard
curve derived with C2-ceramide and analysis using an NIH Image
Program (1.52).
 
Results
 
Protection from Fas-mediated death by linomide.
 
Injection of anti-
Fas antibody causes gross liver injury leading to hepatic failure
and death within 6 h and has been suggested as a model for hu-
man fulminant hepatitis (22). We explored the possible thera-
peutic use of linomide to prevent liver failure, as well as the ef-
fect of anti-Fas administration on other tissues such as thymus,
heart, and ovary. Different concentrations of the Jo2 antibody
were injected intravenously into BALB/c mice, which were ei-
ther untreated or treated with one of two linomide doses (100
and 300 mg/kg/d) (Fig. 1). All untreated mice (18/18) receiving
10 
 
m
 
g of Jo2 antibody died within 6 h, but only 7/23 mice
treated with 100 mg/kg/d and 4/23 mice treated with 300 mg/
kg/d of linomide died. All mice treated with linomide alive 6 h
after Jo2 antibody injection survived for the experimental pe-
riod tested (at least 2 mo, when they were finally killed) with
no sign of disease. Of the mice receiving 1 
 
m
 
g of Jo2, only 1/6
of the untreated mice but none (0/6) of the linomide-treated
group died (not shown). These results confirm the lethal effect
of the Jo2 antibody (22) and show that intravenous injection
required lower doses than intraperitoneal administration to in-
duce the same lethal effect. More importantly, we show that li-
nomide prevented the lethal effect of the anti-Fas antibody in
a dose-dependent manner.
Biochemical analysis of the mouse sera confirmed previous
findings (22) of dramatic increases in the levels of liver specific
enzymes, glutamic pyruvic transaminase (GPT), and glutamic
oxalacetic transaminase (GOT) in serum before death (Table
I). Also of interest is the 30-fold increase in lactate dehydroge-
nase (LDH), representative of release from intracellular stores
due to intensive cell death. Alkaline phosphatase, amylase,
Na
 
1
 
, and K
 
1
 
 
 
increased only marginally (not shown). Linomide
prevented, in a dose-dependent fashion, the sustained increase
of GPT, GOT, and LDH promoted by anti-Fas. Thus, as shown
in Table I, GPT, GOT, and LDH levels decreased to normal
values 72 h after anti-Fas administration. Treating the mice
Figure 1. The effect of linomide administration on the mortality of 
mice inoculated with a lethal dose of anti-Fas antibody. Three differ-
ent groups of 12-wk-old mice injected with 10 mg of Jo2 antibody re-
ceived different doses of linomide in drinking water or water alone. 2 d 
before intravenous injection of 10 mg of Jo2 antibody, the mice re-
ceived linomide in drinking water at a dose of either 100 (dotted line, 
n 5 23) or 300 mg/kg/d (continuous line, n 5 28). Age-matched con-
trol mice (dashed line, n 5 18) received sterile water. Untreated mice 
and those treated with linomide were housed in adjacent cages in the 
same room, under sterile conditions. The data represent the survival 
curves of one experiment out of three performed.
 
Table I. Biochemical Analysis of the Serum of Mice Receiving 
Anti-Fas Antibody Injections and Treated with Linomide
 
Time Linomide GPT GOT LDH
 
(h) (mg/kg/d)
 
(IU1
 
2
 
1
 
) (IU1
 
2
 
1
 
) (IU1
 
2
 
1
 
)
 
0 0 53
 
6
 
12 109
 
6
 
31 1100
 
6
 
250
1 0 295
 
6
 
65 607
 
6
 
190 2600
 
6
 
590
1 100 106
 
6
 
28 250
 
6
 
72 1200
 
6
 
310
1 300 72
 
6
 
22 122
 
6
 
39 1030
 
6
 
210
3 0 16300
 
6
 
2500 16100
 
6
 
3100 37600
 
6
 
5100
3 100 15600
 
6
 
1800 12700
 
6
 
2200 32200
 
6
 
4300
3 300 5600
 
6
 
1500 5200
 
6
 
1100 10400
 
6
 
1700
24 300 760
 
6
 
210 540
 
6
 
180 ND
48 300 160
 
6
 
42 210
 
6
 
63 ND
72 100 106
 
6
 
25 140
 
6
 
31 1040
 
6
 
180
72 300 80
 
6
 
17 140
 
6
 
25 980
 
6
 
150
 
Purified (10 
 
m
 
g/mouse) anti-Fas antibody (Jo2) in 200 
 
m
 
l of PBS was in-
jected intravenously into 12-wk-old BALB/c mice which had been ad-
ministered different linomide concentrations (100 or 300 mg/kg/d) in
drinking water for 48 h. At the times indicated, blood samples were col-
lected and various biochemical parameters quantified using a standard
automatic clinical analyzer. The results show the values obtained in one
experiment out of three performed, and represent the mean and standard
deviation obtained using four mice/group. IUl, international units/liter.
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with linomide concentrations below 100 mg/kg/d had no effect
on survival. Concentrations above 300 mg/kg/d are difficult to
achieve by oral administration, since mice drink less or refused
water due to the change in taste, and the systemic levels of li-
nomide are consequently more difficult to control. We con-
clude that linomide prevents, in a dose-dependent manner, the
progressive liver damage induced by anti-Fas antibody, and
that these results indicate that the mice quickly and fully re-
cover the biochemical profile and hepatic structure if appropri-
ate treatment is given.
 
Linomide prevents liver and thymus destruction.
 
Tissue sec-
tions from all the mouse organs were examined histologically
at intervals ranging from 50 min to 96 h after intravenous injec-
tion. The injection of 0.1 and 1.0 
 
m
 
g of anti-Fas antibody did
Figure 2. Liver sections of mice injected with 10 mg of Jo2 with no treatment (A and C) or receiving 300 mg/kg/d of linomide (B, D, E, and F). A 
and B show 40 min after injection (the inset in A and the arrow in A and B indicate a focus of apoptotic cells), while C shows a diffuse hemor-
rhage and massive apoptotic death of hepatocytes and D shows only multiple foci of apoptotic cells (indicated by arrows). E and F are 4 d after 
treatment, showing a lack of apoptosis and a regenerative pattern of liver cells. A, 3100, inset 31,000; B and C, 3400; D and E, 3200; F, 3400.
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not produce hepatic lesions. Animals receiving 10 
 
m
 
g of Jo2
which were not linomide treated (Fig. 2 
 
A
 
) and those treated
with 100 mg/kg/d of linomide showed scattered hepatic foci of
apoptotic cells 50 min after injection. Mice receiving 300 mg/
kg/d of linomide produced either spotty or no hepatic apop-
tosis (Fig. 2 
 
B
 
). A dramatic picture appeared 2–3 h after injec-
tion. Untreated animals showed grossly evident diffuse hemor-
rhage with massive and diffuse hepatocyte apoptosis, where
virtually no live hepatocytes are detected (Fig. 2 
 
C
 
). When the
hepatocytes were quantitated under high-power magnifica-
tion, 
 
.
 
 90% were undergoing apoptosis. However, animals re-
ceiving 100 or 300 mg/kg/d of linomide showed less apoptosis
and little or no hemorrhage (Fig. 2 
 
D
 
). In contrast to untreated
mice, when mice received linomide, the frequency of hepato-
cytes undergoing apoptosis was 
 
, 
 
50%. After 48 h, the livers
of surviving animals (all receiving linomide) had fully recov-
ered their normal structure. A high mitotic index (4–5/HPF)
and a “regenerative pattern” of liver cells were the only signs
Figure 3. Thymus sections from mice receiving linomide (300 mg/kg/d) (A and B); injected 50 or 360 min earlier with 10 mg of Jo2 antibody (C 
and D, respectively); or injected 4 d earlier with 10 mg/mouse Jo2 antibody and receiving 300 mg/kg/d linomide (E and F). The arrow in C indi-
cates pyknosis and phagocytosis with a starry-sky pattern, and in D, an organoid pattern of epithelial cells. A, D, and E, 340; B, C, and F, 3400.
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of a previous lesion. 4 d later, the liver cells still showed regen-
erative characteristics, but the mitotic index was lower (1–2/
HPF) (Fig. 2 E) and more clearly visualized, as shown under
high-power magnification in Fig. 2 F.
Histological analysis was also performed on the thymus.
When compared with that of untreated mice (Fig. 3, A and B),
the thymus showed morphological changes only after injection
of 10 mg of Jo2. 50 min after injection, pyknosis and phagocy-
tosis of cortical thymocytes displaying a classical starry-sky
pattern appeared (Fig. 3 C) and 3 h later, an involutive ten-
dency was evident, with clear medullary widening and cortical
thinning (Fig. 3 D). 4 d later, the surviving animals which had
been treated with 100 or 300 mg/kg/d of linomide showed less
marked or no atrophy (Fig. 3 E), less prominent pyknosis and
phagocytosis, and absence of the prominent starry-sky pattern
(Fig. 3 F). The lung, heart, gastrointestinal tract, kidney, and
pancreas showed no pathological changes at any time or lino-
mide dose. Findings in the ovary were not consistent, probably
due to the fact that animals had not been selected on the basis
of the sexual cycle.
As shown above, anti-Fas antibody injection obliterated
mostly cortical thymocytes. The surviving thymic cell popula-
tion in linomide-treated mice, based on histopathological find-
ings, showed massive cell death 24 h after anti-Fas injection
(120 3 106 thymocytes in untreated mice vs. 34 3 106 thy-
mocytes in linomide-treated mice), which continued 96 h after
injection. Most surprising was the clear shift in Fas expression
72 h after anti-Fas injection (Fig. 4 A). The thymic population
which expressed intermediate levels of Fas (double-positive
thymocytes) died, while cells expressing either high or low Fas
levels survived. Fas or CD3 expression levels are not modified
by linomide treatment as detected in cytofluorometric analysis
using FITC-labeled anti-CD3 antibodies. In fact, the mean fluo-
rescence intensity for Fas expression is 58.6 and 60.3 for un-
treated and linomide-treated mice, respectively, which in the
case of CD3 expression is 48.5 and 49.2 in untreated and lino-
mide-treated mice, respectively (here considering the bright
CD31 cells). As shown in Fig. 4 B, selective depletion of dou-
ble-positive (CD41CD81) thymocytes resulted in the prefer-
ential survival of mature, bright CD3 thymocytes. Thus, dou-
ble staining with anti-CD4 and anti-CD8 antibodies reveals
that from 82%, CD41CD81 double-positive thymocytes de-
creased to almost background levels 48 h after anti-Fas admin-
istration. The selective decrease in CD41CD81 thymocytes is
associated with an increase in CD42CD82 T cell precursor fre-
quencies as well, as in CD31CD41CD82 and CD31CD42CD81
mature T cells (Fig. 5). The enrichment of mature thymocytes
after Jo2 injection correlated with enhanced proliferative re-
sponses obtained in vitro after anti-CD3 stimulation. Thy-
mocytes from mice injected with 10 mg of Jo2 antibody and re-
ceiving 300 mg/kg/d of linomide, when stimulated in vitro in
microtiter plates coated with anti-CD3e antibodies, showed a
twofold increase in proliferation compared with thymocytes
from untreated mice, as measured by [3H]thymidine uptake
(not shown) (21). These results show that mature CD31CD42/
CD82 thymocytes are resistant to cell death induced by anti-
Fas antibodies in the presence of linomide, while linomide
does not prevent the cell death of immature CD1CD81 corti-
cal thymocytes.
Linomide prevents accumulation of ceramide. Fas binding
by antibodies activates sphingomyelinase and generates cera-
mide (5). Moreover, Fas-sensitive cell lines tested could be in-
duced to apoptosis after exposure to cell-permeable C2-cera-
Figure 5. The anti-Fas antibody kills off immature CD41CD81 thy-
mocytes. BALB/c mice receiving linomide in drinking water were 
injected with anti-Fas antibody Jo2 or left untreated. After 48 h, sur-
viving mice were tested for CD4, CD8, and CD3 expression using 
FITC-labeled anti-CD4 and PE-labeled anti-CD8 antibodies or PE-
labeled anti-CD4 and anti-CD8 and FITC-labeled anti-CD3 antibod-
ies. The figure shows the staining obtained with thymocytes from 
mice treated with linomide alone (left) or mice also receiving anti-Fas 
antibody (right).
Figure 4. Expression of Fas and TCR-CD3 by thymocytes before 
(solid line) and after injection with Jo2 antibody (dark line) into lino-
mide-treated mice (300 mg/kg/d). Expression was tested by FACS® 
analysis 72 h after in vivo intravenous injection using anti-Fas antibody 
(A) or anti-CD3 antibody (B), followed by FITC-labeled anti–hamster 
antibody. Reactivity of an irrelevant, isotype-matched antibody is rep-
resented by the dotted line.
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mide, indicating that ceramide may be an intracellular
messenger leading to apoptotic cell death (24). The production
of ceramide by anti-Fas treatment has only been tested previ-
ously in hematopoietic cells (25), so we tested hepatocyte and
thymus ceramide production. Mice received intravenous injec-
tions of progressively increasing concentrations of Jo2 anti-
body (0.2–20 mg/mouse) and the liver was analyzed from 5 to
50 min later. Ceramide production was measured as described
by the DAG kinase assay (5) and the results are shown in Fig.
5. Mice injected with anti-Fas antibody, both linomide-treated
as well as untreated, showed an increase in ceramide levels in
liver, which lasts for 5 min, and also occurs in PBS-injected
mice. We believe this is a consequence of stress produced by
manipulation (not shown). More relevant is that, in mice re-
ceiving anti-Fas antibody, ceramide levels increased for up to
15 min, decreasing thereafter, while in the presence of lino-
mide, ceramide levels decreased to those found in untreated
mice (Fig. 6). Of interest, when thymus samples were analyzed
for ceramide, we found that the anti-Fas antibody, in contrast
to the case for liver, does not trigger an increase in ceramide
levels (Fig. 6). We conclude that linomide prevents the apop-
totic death of hepatocytes as well as the accumulation of cera-
mide after Fas ligation. Furthermore, although some hepato-
cytes die, as shown by increased GPT, GOT, and LDH levels,
this destruction is self-limited and transient in the present of li-
nomide; the liver regenerates morphologically and function-
ally within 72 h, for the remainder of the animal’s life.
Discussion
Apoptosis appears to be an important regulator of immune re-
sponse and inflammation during viral and bacterial infection
(1). Growing evidence is being presented that apoptosis is
closely controlled by various gene products which promote cell
death. Among them, the Fas antigen, abundantly expressed in
the thymus, liver, heart, lung, kidney, and ovary, has being
identified recently as the putative surface molecule capable of
transducing apoptotic signals into cells (26). A cytotoxic anti-
body against mouse Fas has been shown to kill wild-type mice
by inducing massive liver destruction (22).
The liver plays a central and varied role in many essential
physiologic processes, and liver failure constitutes the final
outcome of many diseases ranging from metabolic, viral, para-
sitic, bacterial, and fungal infections, to drug-induced and sus-
tained inflammatory processes. These processes, independent
of the triggering mechanisms, involve hepatic apoptosis which,
when uncontrolled, threatens the individual’s life by fulminant
hepatitis. A number of experimental animal models are cur-
rently available to screen and test new pharmacological com-
pounds designed to curtail massive hepatic apoptosis. Re-
cently, abnormal activation of the Fas-Fas ligand interaction
was shown to play a role in cell death, including hepatocyte
death (13–21). Consequently, transgenic mice carrying the hu-
man hepatitis virus B on an albumin promoter and injected
with CTLs specific for the HBV antigen and mice injected with
anti-Fas antibodies appear to represent good models for hu-
man fulminant hepatitis (27, 28).
Liver destruction also occurs when several polyclonal stim-
ulators, such as bacterial lipopolysaccharide (29), bacterial en-
terotoxins (i.e., Staphylococcus aureus B) (30), or anti-CD3e
antibodies (31), are administered in vivo. They induce a series
of toxic effects denominated septic shock, which includes hy-
perthermia, hypothermia, bradycardia, cardiovascular and
liver destruction, leading to death (32). The pathology of septic
shock is mediated by the interplay between various cytokines,
among which TNF plays a critical role (32, 33). Accordingly,
passive immunization against TNF improved survival in differ-
ent animal models of LPS-mediated septic shock (34). Using
four distinct models, we have shown previously that linomide
prevents septic shock in mice (6, 8) and that it partially blocks
TNF production (up to 60%), both in vivo and ex vivo (6, 8).
We have now carried the analysis one step further and have
shown that, in hepatocytes, linomide also prevents accumula-
tion of ceramide induced by Fas ligation. Therefore, it appears
that the protective role of linomide in septic shock survival is
mediated by the two actions, inhibition of TNF production and
ceramide accumulation, in hepatocytes. Our results show that
linomide not only prevents septic shock (in which experimen-
tal animals die of liver failure), but also liver destruction trig-
gered by other means, and therefore, linomide may be a good
candidate for the treatment of fulminant hepatitis.
It appears that ceramide may act as a physiological media-
tor of cell death (35–37). In fact, ceramide transduces the
effects of TNF-a (locally produced after hepatitis B viral infec-
tion) (38), as well as Fas ligation and perhaps other extracellu-
lar agents, on cell death. It has not escaped our attention that
the prevention of ceramide accumulation by linomide suggests
additional uses for linomide in degenerative diseases associ-
Figure 6. Ceramide accumulation after anti-Fas 
injection. Mice given linomide or untreated were 
intravenously injected with 15 mg/mouse of Jo2 
antibody. 15 min after Jo2 injection, mice were 
killed, their livers (filled bars) and thymuses 
(hatched bars) collected, and lipids extracted 
and assayed with E. coli DAG kinase. Lipids 
were separated by TCL and radioactive spots 
were visualized by autoradiography. Ceramide 
and DAG controls were included in the assay 
and quantitative results for ceramide-1-phos-
phate accumulation were obtained by scanning 
the autoradiograph and analyzing the results us-
ing the NIH Image Program 1.52, as described in 
Methods. The figure shows the mean and the 
standard error of the means obtained in three 
different experiments.
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ated with cell death. Experiments are currently underway to
test this possibility. Thus, apoptosis mediated by Fas may have
a broader implication for the immune response and autoim-
mune disease in general. For example, apoptosis has been ob-
served in freshly isolated T cells from HIV-infected individu-
als, but not from uninfected individuals (39). Thus, apoptosis
may play a role in the diminution of CD41 T cells and the pro-
gression to AIDS in HIV-infected individuals. If so, therapeu-
tic intervention for HIV-infected individuals with a Fas antag-
onist may be possible and linomide may become a useful
target for pharmacological intervention.
In this manuscript, we also show that linomide acts by re-
ducing Fas-induced apoptosis. In contrast, after Fas and lino-
mide treatment, thymocytes retain this striking Fas-related se-
lection. Indeed, only mature thymocytes survive Fas-mediated
killing. The inability of linomide to promote double-positive
thymocyte survival correlates with previous results showing its
inability to prevent in vivo glucocorticoid-induced pro-
grammed cell death in thymocytes, while being effective in
splenocytes (6). The differential susceptibility of thymus and
peripheral T cells to linomide might reflect the existence of
more than one pathway in the induction of apoptosis. In fact, it
is well illustrated that Fas-Fas ligand interaction actively par-
ticipates in the homeostasis of spleen T cells, while it has no
role in the thymus (40).
Our results showing that Fas ligation does not trigger accu-
mulation of ceramide in the thymus are therefore relevant in
two contexts. First, they support the view that prevention of
apoptosis and inhibition of ceramide accumulation might be
linked. Second, the pathway through which Fas ligation trig-
gers apoptosis may not be the same in different cell lineages
and therefore, additional effector molecules specific for apop-
tosis in thymocytes might be activated. Finally, these data indi-
cate that linomide might have some other function besides
preventing apoptosis, since ceramide production, also associ-
ated with cytokine responses, does not always trigger apoptosis.
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